Quanterix Advances Alzheimer's Diagnostic to H2 FDA Review, Names New CFO
Summary
Quanterix appointed Jason Faessler as its new CFO, effective June 22, 2026, following the previously announced departure of Vandana Sriram and the 8-K filing on June 9th. Crucially, the company is advancing a five-marker Alzheimer's diagnostic for expected FDA review in the second half of the year. This development is a significant step towards commercialization, supported by plans to boost commercial operations and R&D, with a target of achieving cash-flow breakeven by year-end.
At the time of this announcement, QTRX was trading at $3.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145.6M. The 52-week trading range was $2.40 to $8.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.